Slides are available to download in PDF below. Further slides still being added, so check back if the one you want isn't up yet!

STOP TB MEETING - Thursday, Feb. 27, 2014

Video-Conferencing

1. Global Epidemiology of MDR-TB
Dr. Matteo Zignol, World Health Organization, Geneva, Switzerland

2. Global Laboratory Initiative
Dr. Thomas Shinnick, Centers for Disease Control and Prevention, Atlanta, GA, USA

3. The Global Drug Facility - Not available
Dr. Joel Keravec, World Health Organization, Geneva, Switzerland

4. MDR-TB and Palliative and End-of-life Care
Dr. Ernesto Jaramillo, World Health Organization, Geneva, Switzerland

Live Presentations:

5. What Will It Take?
Dr. Randall Reves, University of Colorado School of Medicine and Public Health, Denver, CO, USA

Oral Abstract Presentation: Measuring the Impact of Community Engagement on TB Clinical Trials: A Case Study from the TB Trials Consortium
Mr. Mike Frick, Treatment Action Group, New York, NY, USA

Oral Abstract Presentation: Active Tuberculosis Case Finding Post-Earthquake in a Slum Community in Port-au-Prince, Haiti
Mr. Jack Masur, Les Centres GHESKIO, Port-au-Prince, Haiti

NURSING SPONSORED SESSION - Thursday, Feb. 27, 2014

1. Managing Complex Cases
Mr. Denis Francis, McGill University Health Centre, Montreal, QC, Canada

2. Managing Cases through Building Relationships
Dr. Lisa Gurland, Lemuel Shattuck Hospital – Massachusetts Department of Public Health, Boston, MA, USA

3. Managing Cases Across Borders - US, Mexico and Central America
Dr. Carlos Vera-Garcia, Cure TB, Binational TB Program, San Diego, CA, USA

4. Story Telling and First Nations Narratives - Facilitating Teaching and Learning Opportunities about Tuberculosis in British Columbia, Canada
Ms. Shawna Buchholz, British Columbia Centre for Disease Control, Vancouver, BC, Canada

5. Promoting Efficacy of TB Prevention and Treatment in Native American Communities - Community Control, Cultural Relevance and Partnership
Ms. Denise Genaro Wolf, Public Health Seattle King County, Seattle, WA, USA

6. Educational Resources and Approaches for Managing Complex TB Cases
Ms. Nisha Ahamed, NJMS Global TB Institute, Newark, NJ, USA

BEYOND TB LECTURE: Community-Based Care of Chronic Infectious Disease
Dr. Paul Farmer, Harvard Medical School/Partners in Health, Boston, MA, USA

THE GEORGE COMSTOCK LECTURE: Contemporary TB Control: The Perfect Mix of Science of Science, Technology, Marketing and Management Capacity
Dr. Catharina van Wezeenbeek, KNCV, The Hague, Netherlands

MULTI-DRUG RESISTANT TB  - Friday, Feb. 28, 2014

1. Epidemiology of MDR TB in North America/Caribbean Regions
Dr. Patrick Moonan, Centers for Disease Control and Prevention, Atlanta, GA, USA

2. TB Drug Pipeline and New Treatment Combinations for MDR TB
Dr. Robert Horburgh Jr., Boston University School of Public Health, Boston MA, USA

3. Management of LTBI Caused by MDR-XDR Isolates - The Cons of Susceptibility Driven Treatment
Dr. Sundari Mase, Centers for Disease Control and Prevention, Atlanta, GA, USA
Dr. David Ashkin, Florida Department of Public Health, Lantana, FL, USA

4. Approach to Fast Track Laboratory Diagnosis for Persons at Risk of Drug Resistant TB
a) Molecular Detection of Drug Resistance (MDDR) Service - Dr. Beverly Metchock, Centers for Disease Control and Prevention, Atlanta, GA, USA
b) Advanced Diagnostic Laboratories - Dr. Max Salfinger, National Jewish Medical and Research Center, Denver, CO, USA

Oral Abstract Presentation: Drug Resistance Profiles among Patients Enrolled in a Cohort Study of TB in Lima, Peru
Mr. Roger Ivan Calderon Espinoza, Socios en Salud Sucursal, Lima, Peru

Oral Abstract Presentation: Against All Odds- Early Success Treating MDR TB in the US Pacific
Dr. Richard Brostrom, Centers for Disease Control and Prevention, Honolulu, HI, USA

THE DIFFICULT TO TREAT PATIENT - Friday, Feb. 28, 2014

1. Co-morbidities in TB Diagnosis - Risk Factors for Activation
Dr. Marie Turner, Lemuel Shattuck Hospital, Jamaica Plain, MA, USA

2. Tuberculosis and the Complications of a Substance Abusing Client
Dr. Karina Forrest –Perkins, Prevent Child Abuse Minnesota, Saint Paul, MN, USA

3. Solving the Silent Crisis - Advocacy Strategies to Resolve and Prevent Domestic Drug Shortages
Mr. Kenyon Farrow, Treatment Action Group, New York, NY, USA

4. The Hard to Treat Pediatric/Adolescent Patient - Not available
Dr. Ian Kitai and Mr. Ray Lam, Hospital for Sick Children/University of Toronto, Toronto, ON, Canada

Oral Abstract Presentation: Tuberculosis Exposure, Infection, and Disease among Children with Medical Co-morbidities
Dr. Andrea Cruz, Baylor College of Medicine, Houston, TX, USA

Oral Abstract Presentation: Diabetes Knowledge and Self-Management among Tuberculosis Patients in Hawaii, 2013
Dr. Bonnie Young, State of Hawaii Department of Health, TB Control Branch, Honolulu, HI, USA

 

FROM THE LABORATORY TO YOUR CLINICAL PRACTICE - Saturday, March 1, 2014

1. Targeting the Organism- Present and Future
Dr. Anna Upton, TB Alliance, New York, NY, USA

2. The Host: Immunology and Implications for Vaccines
Dr. Tom Evans, AERAS, Rockville, MD, USA

3. Genotyping for the Diagnosis of Drug Resistant TB
Dr. Megan Murray, Harvard School of Public Health, Boston, MA, USA

4. Rapid Point -of -Care Breath Test for Tuberculosis
Dr. Michael Phillips, Menssana Research Inc, Fort Lee, NJ, USA

Oral Abstract Presentation: Novel katG Mutations Identified in Mycobacterium tuberculosis Provide a More Comprehensive Diagnostics for Isoniazid Resistance and Better Clinical Management of Drug Resistant TB
Dr. Fararmarz Valafar, San Diego State University, San Diego, CA, USA

Oral Abstract Presentation: IGRA Testing Using a Portable Incubator
Dr. Maureen Mayhew, BC Centre for Disease Control, Vancouver, BC, Canada

LATENCY - Saturday, March 1, 2014

1. Evolving Science of Latency: Potential Implications on the Diagnosis and Treatment of LTBI - Not  available
Dr. JoAnne Flynn, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

2. Programmatic Experience with IGRA Testing
Dr. Julie Higashi, Curry International TB Center, San Francisco, CA, USA

3. Programmatic Experience with the 12 Dose Rifapentine/Isoniazid Regimen in the US
Dr. Christine Ho, Centers for Disease Control and Prevention, Atlanta, GA, USA

4. The Impact of Screening and Treatment of LTBI on TB Control and Incidence
a) Screening and Treatment as Population-Based Control Strategies in Low TB Incidence Settings - Dr. Tim Sterling, Vanderbilt University, Nashville, TN, USA
b) The Limits of Screening and Treatment for Latent TB as a TB Control Strategy - Dr. Kevin Schwartzman, McGill University, Montreal, QC, Canada

Oral Abstract Presentation: Outcomes of Latent Tuberculosis Screening and Therapy in Transplant Candidates and Recipients over a 10 Year Period
Dr. Aman Sidhu, University of Alberta, Edmonton, AB, Canada

Oral Abstract Presentation: Factors Associated with Non-Completion of Latent Tuberculosis Infection (LTBI) Treatment: Experiences from the PREVENT TB STUDY
Dr. Ruth Moro, Centers for Disease Control and Prevention, Atlanta, GA, USA

Questions?

Dr. Menn Biagtan

Program Manager

BC Lung Association

E biagtan@bc.lung.ca

T 604.731.5864

F 604.731.5810


 

Privacy Statement & Disclaimer